Lupin, a leading global pharmaceutical company, has announced the acquisition of the Huminsulin product line from Eli Lilly and Company in India. This strategic move aims to significantly expand Lupin’s diabetes care portfolio and further its commitment to providing high-quality, affordable healthcare to patients managing diabetes.

Lupin has been marketing the Huminsulin range in India under existing distribution and promotion agreements with Eli Lilly. With this acquisition, Lupin takes full ownership of the product line, which includes a variety of Insulin Human formulations such as Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70.

These insulin products, including Metformin, are commonly prescribed for the treatment of both type 1 and type 2 diabetes mellitus. Insulin therapy is a cornerstone in managing blood sugar levels for individuals with type 1 diabetes and is also crucial for patients with type 2 diabetes as the disease progresses.

Nilesh Gupta, Managing Director of Lupin, expressed his enthusiasm about the acquisition, stating, “This acquisition is strategic to our ongoing efforts to expand our diabetes portfolio and provide high-quality, affordable healthcare to our patients. It reinforces our unwavering commitment to combating diabetes and providing comprehensive care.”

Rajeev Sibal, President of India Region Formulations at Lupin, also highlighted the significance of the acquisition, saying, “Lupin has been at the forefront of providing holistic diabetes care to patients. This acquisition further strengthens our diabetes portfolio and enables us to offer a broad range of human insulin options to millions of patients, thereby helping them lead healthier lives.”

Diabetes is a growing health concern in India, where the prevalence of both type 1 and type 2 diabetes continues to rise. The acquisition of the Huminsulin range is a pivotal step for Lupin in addressing the increasing demand for insulin therapies, which are essential for blood sugar control in diabetic patients. With the acquisition, Lupin aims to enhance its existing portfolio of diabetes treatments and offer a wider range of insulin options to the millions of people living with diabetes in India.

The Indian market for diabetes care is poised for growth, and Lupin’s decision to acquire Huminsulin signals the company’s focus on strengthening its position in this critical therapeutic area. Lupin’s expanded portfolio will enable the company to cater to a broader spectrum of diabetic patients, from those newly diagnosed with type 2 diabetes to long-term type 1 diabetes patients who rely on consistent and effective insulin therapy.